PANIC
MCID: PNC025
MIFTS: 53

Panic Disorder (PANIC)

Categories: Mental diseases, Neuronal diseases, Respiratory diseases

Aliases & Classifications for Panic Disorder

MalaCards integrated aliases for Panic Disorder:

Name: Panic Disorder 12 74 36 54 42 43 15 17 71
Panic Anxiety Syndrome 12
Panic Disorder 1 71
Panic 54

Classifications:



External Ids:

Disease Ontology 12 DOID:594
KEGG 36 H01664
MeSH 43 D016584
NCIt 49 C34890
ICD10 32 F41.0
UMLS 71 C0030319 C1868649

Summaries for Panic Disorder

KEGG : 36 Panic disorder (PD) is a common type of anxiety disorder, characterized by unexpected and repeated panic attacks or fear of future panic attacks. It has a rapid onset and includes symptoms such as palpitations, chest pain, sweating and shaking. Some physical illnesses (e.g. asthma) commonly occur with panic disorder, and certain lifestyle factors (e.g. smoking) increase the risk for the disorder, but causal pathways are still unclear. In recent years, an association was found between panic symptoms and increased activity in the right frontal region of the brain. Genetic susceptibility factors also exist, but their exact nature and pathophysiological mechanisms remain unknown. Cognitive behavioural therapy (CBT) and several medications, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs) and benzodiazepines are effective for PD. Among these, SSRIs and SNRIs are considered to be first-line treatment agents because of their efficacy and favorable side effect profile.

MalaCards based summary : Panic Disorder, also known as panic anxiety syndrome, is related to neurotic disorder and anxiety. An important gene associated with Panic Disorder is MIR22 (MicroRNA 22), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Valproic acid and Etoricoxib have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An anxiety disorder that is characterized by unexpected and repeated episodes of intense fear accompanied by physical symptoms that may include chest pain, heart palpitations, shortness of breath, dizziness, or abdominal distress.

MedlinePlus : 42 Panic disorder is a type of anxiety disorder. It causes panic attacks, which are sudden feelings of terror when there is no real danger. You may feel as if you are losing control. You may also have physical symptoms, such as Fast heartbeat Chest or stomach pain Breathing difficulty Weakness or dizziness Sweating Feeling hot or a cold chill Tingly or numb hands Panic attacks can happen anytime, anywhere, and without warning. You may live in fear of another attack and may avoid places where you have had an attack. For some people, fear takes over their lives and they cannot leave their homes. Panic disorder is more common in women than men. It usually starts when people are young adults. Sometimes it starts when a person is under a lot of stress. Most people get better with treatment. Therapy can show you how to recognize and change your thinking patterns before they lead to panic. Medicines can also help. NIH: National Institute of Mental Health

Wikipedia : 74 Panic disorder is an anxiety disorder characterized by reoccurring unexpected panic attacks. Panic... more...

Related Diseases for Panic Disorder

Diseases in the Panic Disorder family:

Panic Disorder 1 Panic Disorder 2
Panic Disorder 3

Diseases related to Panic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 448)
# Related Disease Score Top Affiliating Genes
1 neurotic disorder 33.3 SLC6A4 MAOA HTR2A HTR1A
2 anxiety 33.2 TSPO TPH2 SLC6A4 SLC6A2 PTK7 MAOA
3 major depressive disorder 33.1 TPH2 SLC6A4 SLC6A2 MAOA HTR3A HTR2A
4 obsessive-compulsive disorder 33.0 TPH2 SLC6A4 PTK7 MAOA HTR3A HTR2A
5 agoraphobia 32.7 SLC6A4 SLC6A2 PTK7 MIR22 MAOA HTR2A
6 depression 32.4 TPH2 SLC6A4 MAOA HTR2A HTR1A CRH
7 social phobia 32.2 SLC6A4 PTK7 MAOA HTR3A HTR1A COMT
8 generalized anxiety disorder 32.1 TSPO SLC6A4 SLC6A2 MAOA HTR3A HTR2A
9 mental depression 32.0 TPH2 SLC6A4 SLC6A2 MAOA HTR3A HTR2A
10 personality disorder 31.9 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
11 substance abuse 31.8 SLC6A4 MAOA HTR2A HTR1A CRH COMT
12 phobia, specific 31.8 SLC6A4 MAOA HTR1A COMT
13 alexithymia 31.7 SLC6A4 HTR1A COMT
14 alcohol use disorder 31.7 SLC6A4 HTR3A HTR2A HTR1A CRH COMT
15 dysthymic disorder 31.7 SLC6A4 MAOA HTR2A HTR1A CRH
16 hypochondriasis 31.7 SLC6A4 HTR3A HTR2A HTR1A
17 mood disorder 31.6 TPH2 SLC6A4 SLC6A2 MAOA HTR3A HTR2A
18 somatization disorder 31.6 SLC6A4 HTR2A HTR1A CRH
19 eating disorder 31.5 SLC6A4 HTR2A CRH COMT CCK
20 irritable bowel syndrome 31.5 SLC6A4 HTR3A HTR2A HTR1A CRH COMT
21 phobic disorder 31.5 SLC6A4 MAOA HTR2A HTR1A CRH COMT
22 sexual disorder 31.5 SLC6A4 HTR3A HTR2A HTR1A
23 endogenous depression 31.4 SLC6A4 MAOA HTR3A HTR2A HTR1A CRH
24 post-traumatic stress disorder 31.4 SLC6A4 MAOA HTR2A CRH COMT
25 alcohol dependence 31.4 TSPO TPH2 SLC6A4 SLC6A2 MAOA HTR3A
26 avoidant personality disorder 31.3 SLC6A4 MAOA
27 migraine with or without aura 1 31.3 SLC6A4 MAOA HTR3A HTR2A HTR1A CRH
28 bipolar disorder 31.3 TSPO TPH2 SLC6A4 SLC6A2 MAOA HTR3A
29 substance dependence 31.3 SLC6A4 MAOA CRH COMT
30 sleep disorder 31.2 SLC6A4 HTR2A HTR1A
31 bulimia nervosa 31.2 SLC6A4 MAOA HTR3A HTR2A CRH COMT
32 constipation 31.2 SLC6A4 SLC6A2 HTR3A CCK
33 body dysmorphic disorder 31.1 SLC6A4 MAOA HTR2A
34 borderline personality disorder 31.1 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
35 somatoform disorder 31.1 SLC6A4 HTR3A COMT
36 bipolar i disorder 31.1 TPH2 SLC6A4 HTR2A HTR1A COMT
37 fibromyalgia 31.1 TSPO SLC6A4 HTR3A HTR2A CRH COMT
38 attention deficit-hyperactivity disorder 31.1 TSPO TPH2 SLC6A4 SLC6A2 MAOA HTR2A
39 obsessive-compulsive personality disorder 31.0 SLC6A4 HTR2A
40 tobacco addiction 31.0 SLC6A4 MAOA HTR2A COMT
41 acute stress disorder 31.0 SLC6A4 CRH
42 amnestic disorder 31.0 TSPO HTR3A HTR1A
43 adjustment disorder 30.9 TSPO SLC6A4 HTR2A
44 melancholia 30.9 SLC6A4 MAOA HTR2A HTR1A CRH
45 premature ejaculation 30.9 SLC6A4 HTR3A HTR1A COMT
46 postpartum depression 30.9 SLC6A4 MAOA HTR1A CRH COMT
47 schizoaffective disorder 30.8 SLC6A4 HTR2A HTR1A COMT
48 paranoid schizophrenia 30.8 TPH2 SLC6A4 MAOA HTR2A HTR1A COMT
49 psychotic disorder 30.8 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
50 tic disorder 30.8 TPH2 SLC6A4 MAOA HTR2A COMT

Graphical network of the top 20 diseases related to Panic Disorder:



Diseases related to Panic Disorder

Symptoms & Phenotypes for Panic Disorder

GenomeRNAi Phenotypes related to Panic Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Panic Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 CCKAR CCKBR COMT CRH HTR1A HTR2A
2 homeostasis/metabolism MP:0005376 9.93 CCK CCKAR CCKBR COMT CRH HTR1A
3 endocrine/exocrine gland MP:0005379 9.91 CCK CCKAR CCKBR COMT CRH HTR2A
4 nervous system MP:0003631 9.73 CCK CCKAR CCKBR COMT CRH HTR1A
5 renal/urinary system MP:0005367 9.17 CCK CCKAR CCKBR COMT CRH HTR3A

Drugs & Therapeutics for Panic Disorder

Drugs for Panic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
2
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
3
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
4
Norepinephrine Approved Phase 4 51-41-2 439260
5
Propranolol Approved, Investigational Phase 4 525-66-6 4946
6
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
7
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
8
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
9
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
10
Clozapine Approved Phase 4 5786-21-0 2818
11
Ziprasidone Approved Phase 4 146939-27-7 60854
12
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
13
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
14
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
15
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
16
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
17
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
18
Suvorexant Approved, Investigational Phase 4 1030377-33-3
19
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
20
Promethazine Approved, Investigational Phase 4 60-87-7 4927
21
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
22
Sertraline Approved Phase 4 79617-96-2 68617
23
Alprazolam Approved, Illicit, Investigational Phase 4 28981-97-7 2118
24 Cyclooxygenase 2 Inhibitors Phase 4
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4
26 Cyclooxygenase Inhibitors Phase 4
27 Antirheumatic Agents Phase 4
28 Neurotransmitter Agents Phase 4
29 Serotonin Uptake Inhibitors Phase 4
30 Cytochrome P-450 Enzyme Inhibitors Phase 4
31 Psychotropic Drugs Phase 4
32 Antidepressive Agents Phase 4
33 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
34 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
35 Duloxetine Hydrochloride Phase 4
36 Anti-Arrhythmia Agents Phase 4
37 Antihypertensive Agents Phase 4
38 Adrenergic Antagonists Phase 4
39 Adrenergic beta-Antagonists Phase 4
40 Adrenergic Agents Phase 4
41 Antipsychotic Agents Phase 4
42 Quetiapine Fumarate Phase 4 111974-72-2
43 Serotonin 5-HT3 Receptor Antagonists Phase 4
44 Serotonin 5-HT1 Receptor Agonists Phase 4
45 Serotonin Antagonists Phase 4
46 Dopamine Antagonists Phase 4
47 Dopamine agonists Phase 4
48 Serotonin 5-HT2 Receptor Antagonists Phase 4
49 Dopamine D2 Receptor Antagonists Phase 4
50 Contraceptives, Oral Phase 4

Interventional clinical trials:

(show top 50) (show all 361)
# Name Status NCT ID Phase Drugs
1 Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release Unknown status NCT00492414 Phase 4 Paroxetine CR
2 A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder. Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
3 Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures Unknown status NCT00755521 Phase 4 etoricoxib
4 A Randomized, Double-Blind, Multicenter Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder Completed NCT00677352 Phase 4 sertraline;Paroxetine
5 Phase 4 Study of Panic Disorder That Expresses to Change of Cerebral Glucose Metabolism After 12 Week of Paroxetine Treatment Completed NCT00767754 Phase 4 Paxil CR
6 The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder Completed NCT00438971 Phase 4 Duloxetine
7 Changes of Cerebral Glucose Metabolism Associated With the Fear Network Activity Before and After 12 Weeks of Escitalpram Treatment in Panic Disorder Completed NCT00767871 Phase 4 Lexapro
8 Randomized Controlled Trial of Escitalopram Versus Placebo for Patients With Irritable Bowel Syndrome and Panic Disorder Completed NCT01551225 Phase 4 Escitalopram
9 A Randomized, Controlled Trial on the Effects of Paroxetine Versus Placebo in Combination With Aerobic Exercise or Relaxation Training in the Treatment of Panic Disorder Completed NCT00540098 Phase 4 paroxetine + aerobic exercise;Paroxetine + relaxation;Placebo + aerobic exercise;Placebo + relaxation
10 The Effects of Treatment With Sertraline for Panic Disorder and/or Depression Driven Chest Pain and/or Palpitations in a Double Blind, Care as Usual and Placebo Controlled Study Completed NCT01114100 Phase 4 sertraline;placebo
11 An 8-week, Randomized, Double-Blind, Placebo-Controlled Trial of Seroquel SR Co-administration for SSRI-Resistant, Comorbid Panic Disorder Completed NCT00619892 Phase 4 quetiapine XR;placebo
12 A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder Completed NCT02395510 Phase 4 Vortioxetine
13 A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Current at Least Moderately Severe Anxiety and Lifetime Panic Disorder or Generalized Anxiety Disorder Completed NCT00167479 Phase 4 risperidone (Risperdal)
14 Aripiprazole for the Treatment of Refractory Anxiety: Impact on Clinical Outcomes, Resilience and Neuroendocrinologic Parameters Completed NCT00438386 Phase 4 Aripiprazole
15 Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment: a Clinical Randomized Trial Completed NCT00803400 Phase 4 Alprazolam;Alprazolam + Aerobic exercise
16 Combined Treatment With A Benzodiazepine (Clonazepam) And A Selective Serotonin Reuptake Inhibitor (Paroxetine) For Rapid Treatment Of Panic Disorder With Depression Completed NCT00031317 Phase 4 Paroxetine;Clozapine
17 A Multicenter, Randomized, Open-label, Parallel Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder Completed NCT00266409 Phase 4 Niravam;SSRI/SNRI
18 A Randomized Double-Blind Comparison of Sertraline With Early Alprazolam XR Co-Administration vs Sertraline/Placebo for Primary Care Panic Disorder Patients Completed NCT00198094 Phase 4 Sertraline and Alprazolam XR
19 Long-term, Open, Naturalistic, Randomized Clinical Trial With Clonazepam and Paroxetine in Panic Disorder With or Without Agoraphobia Completed NCT02852577 Phase 4 Clonazepam;Paroxetine
20 A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder Completed NCT01172652 Phase 4 Ziprasidone;Placebo
21 Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes Completed NCT00347269 Phase 4 Psychotropic medication optimization
22 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients (MOSAIC) Completed NCT01201967 Phase 4
23 A Randomized Controlled Trial of Cognitive Behavioural Therapy for Non-cardiac Chest Pain and Palpitations. Completed NCT00623454 Phase 4
24 12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
25 Investigation of Genetic Predictors of the Response to SSRI Treatment Completed NCT03927950 Phase 4 escitalopram;bupropion
26 Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
27 A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Immediate-Release Formulation of Quetiapine Fumarate as Potentiation of Selective Serotonin Reuptake Inhibitors, and Serotonin Norepinephrine Reuptake Inhibitors Treatment in Major Depression With Comorbid Anxiety Symptoms Completed NCT00229645 Phase 4 Quetiapine Fumarate (Seroquel®)
28 Single-Site, Double-Blind, Flexible-Dose, Placebo-Controlled Study of the Efficacy, Tolerability, & Safety of Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
29 Pharmacotherapy in Depression With Panic Spectrum Completed NCT00177996 Phase 4 sertraline hydrochloride
30 Cannabinoid Control of Fear Extinction Neural Circuits in Humans Completed NCT02472847 Phase 4 Dronabinol;Placebo
31 Psychophysiology of Delayed Extinction and Reconsolidation in Humans Completed NCT01631682 Phase 4 Propranolol;Mifepristone;Intranasal oxytocin
32 Comparative Effectiveness of Mindfulness-Based Stress Reduction and Pharmacotherapy for Anxiety Recruiting NCT03522844 Phase 4 Escitalopram
33 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Recruiting NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
34 A Pragmatic Randomized Comparator Trial of Eszopiclone and Brief Behavioral Therapy for Insomnia in CPAP Non Adherent Veterans With PTSD and Complex Insomnia Recruiting NCT03937713 Phase 4 eszopiclone
35 Effects of Perampanel on Neurophysiology Test Perimeters Recruiting NCT03653741 Phase 4 Perampanel 6 MG
36 The Role of Orexin in Human Panic Disorder Active, not recruiting NCT02593682 Phase 4 suvorexant;placebo
37 Efficacy of Rapid-Acting NMDA Antagonist for Treatment of Adolescent Depression and Anxiety Disorders Active, not recruiting NCT02579928 Phase 4 Ketamine;Midazolam
38 An Open-Label Study to Assess the Safety and Tolerability of Xanax XR in the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks Terminated NCT00634790 Phase 4 alprazolam XR
39 A Randomized, Double-Blind, Placebo-Controlled Study of Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder Terminated NCT00635531 Phase 4 alprazolam XR
40 A Randomized, Double-Blind, Placebo-Controlled Study of Continuation Treatment With Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder Terminated NCT00635076 Phase 4 alprazolam XR
41 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
42 Mechanisms of CBT-Treatment Effects in Patients With Panic Disorder and Panic Disorder With Agoraphobia: The Role of Interoceptive Exposure Unknown status NCT01323556 Phase 2, Phase 3
43 A Double-blind, Placebo-controlled, Parallel-group Comparison of Venlafaxine Extended-release Capsules and Paroxetine in Outpatients With Panic Disorder Completed NCT00044772 Phase 3 Venlafaxine ER
44 A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder Completed NCT00038896 Phase 3 Venlafaxine ER
45 Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine. Completed NCT00195598 Phase 3 VENLAFAXINE;Paroxetine
46 Randomized Controlled Trial of Psychodynamic Psychotherapy vs. Applied Relaxation for Panic Disorder Completed NCT00128388 Phase 2, Phase 3
47 Treatment Refractory Panic Disorder Completed NCT00118417 Phase 2, Phase 3 Clonazepam;Sertraline
48 Internet- Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder in a Psychiatric Setting: A Randomized Equivalence Trial Completed NCT00845260 Phase 3
49 A Randomized, Controlled Study of a Stepped-care Model for the Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
50 Dynamic Treatment vs. CBT for Panic Disorder Completed NCT00353470 Phase 3

Search NIH Clinical Center for Panic Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alprazolam
Clomipramine
Clomipramine Hydrochloride
Clonazepam
Diazepam
Fluoxetine
Fluoxetine Hydrochloride
Fluvoxamine
Fluvoxamine Maleate
Imipramine
Imipramine Hydrochloride
Imipramine pamoate
Maprotiline
Maprotiline Hydrochloride
Paroxetine
Paroxetine Hydrochloride
Propranolol
Propranolol Hydrochloride
Sertraline
Sertraline Hydrochloride
Temazepam

Cochrane evidence based reviews: panic disorder

Genetic Tests for Panic Disorder

Anatomical Context for Panic Disorder

MalaCards organs/tissues related to Panic Disorder:

40
Brain, Heart, Testes, Amygdala, Cortex, Thyroid, Pituitary

Publications for Panic Disorder

Articles related to Panic Disorder:

(showing 8866, show less)
# Title Authors PMID Year
1
Cognitive behavioral therapy for postpartum panic disorder: a case series. 61 42
31439043 2019
2
The evaluation of metacognitive beliefs and emotion recognition in panic disorder and generalized anxiety disorder: effects on symptoms and comparison with healthy control. 42 61
31157577 2019
3
Implicit Attachment Schemas and Therapy Outcome for Panic Disorder Treated with Manualized Confrontation Therapy. 42 61
31401628 2019
4
Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 are associated with panic disorder and regulate several anxiety candidate genes and related pathways. 61 46
21168126 2011
5
Platelet serotonin transporter function and heart rate variability in patients with panic disorder. 61 54
20358007 2010
6
Gene variations in the cholecystokinin system in patients with panic disorder. 61 54
20023595 2010
7
Association of a polyadenylation polymorphism in the serotonin transporter and panic disorder. 61 54
19969287 2010
8
Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR). 54 61
18663369 2010
9
The complex global pattern of genetic variation and linkage disequilibrium at catechol-O-methyltransferase. 54 61
18574484 2010
10
The symptomatic profile of panic disorder is shaped by the 5-HTTLPR polymorphism. 54 61
19683026 2009
11
Changes in CCK-4 induced panic after treatment with the GABA-reuptake inhibitor tiagabine are associated with an increase in 3alpha,5alpha-tetrahydrodeoxycorticosterone concentrations. 54 61
19501468 2009
12
CCK as a modulator of cardiovascular function. 54 61
19563885 2009
13
The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects. 54 61
19289240 2009
14
779 TC of CCK-1 intron 1 is associated with postprandial syndrome (PDS) in Japanese male subjects. 54 61
19760980 2009
15
Effects of experimentally induced panic attacks on neuroimmunological markers. 54 61
19023641 2009
16
Sympathetic activity relates to adenosine A(2A) receptor gene variation in blood-injury phobia. 61 54
18629431 2009
17
Impact of loudness dependency of auditory evoked potentials on the panic response to CCK-4. 54 61
18534623 2009
18
Association testing of panic disorder candidate genes using CCK-4 challenge in healthy volunteers. 61 54
18832011 2008
19
The association between serotonin-related gene polymorphisms and panic disorder. 54 61
18436425 2008
20
Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. 54 61
18384079 2008
21
Influence of the catechol-O-methyltransferase val158met genotype on amygdala and prefrontal cortex emotional processing in panic disorder. 54 61
18440204 2008
22
Platelet 18 kDa Translocator Protein density is reduced in depressed patients with adult separation anxiety. 54 61
18054208 2008
23
Respiratory irregularity and stress hormones in panic disorder: exploring potential linkages. 54 61
17557312 2008
24
Lack of association between the serotonin transporter promoter polymorphism (5-HTTLPR) and personality traits in asymptomatic patients with panic disorder. 61 54
18164547 2008
25
Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: reduction by a selective serotonin reuptake inhibitor. 54 61
17613943 2007
26
Lack of association between the Serotonin Transporter Promoter Polymorphism (5-HTTLPR) and Panic Disorder: a systematic review and meta-analysis. 54 61
17705872 2007
27
Meta-analysis of COMT val158met in panic disorder: ethnic heterogeneity and gender specificity. 54 61
17357147 2007
28
Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. 61 54
17318504 2007
29
Reduced serotonin-1A receptor binding in social anxiety disorder. 61 54
16979141 2007
30
HPA axis activity in patients with panic disorder: review and synthesis of four studies. 54 61
16845643 2007
31
Association study of tryptophan hydroxylase 2 gene polymorphisms in panic disorder. 61 54
17123728 2007
32
Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population. 61 54
16822601 2006
33
Association of the Val158Met catechol O-methyltransferase genetic polymorphism with panic disorder. 61 54
16525418 2006
34
The novel brain-specific tryptophan hydroxylase-2 gene in panic disorder. 54 61
16401665 2006
35
Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety. 54 61
16600640 2006
36
The neuronal noradrenaline transporter, anxiety and cardiovascular disease. 54 61
16785272 2006
37
Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. 54 61
16541242 2006
38
Cholecystokinin hyperresponsiveness in functional dyspepsia. 61 54
16718754 2006
39
Evidence that variation in the peripheral benzodiazepine receptor (PBR) gene influences susceptibility to panic disorder. 54 61
16511838 2006
40
Cell-specific repressor or enhancer activities of Deaf-1 at a serotonin 1A receptor gene polymorphism. 61 54
16467535 2006
41
Megestrol attenuates the hormonal response to CCK-4-induced panic attacks. 61 54
16470820 2006
42
Increased prevalence of functional gastrointestinal disorders in panic disorder: clinical and theoretical implications. 54 61
16273019 2005
43
Peripheral-type benzodiazepine receptor binding sites in platelets of patients with panic disorder associated to separation anxiety symptoms. 61 54
15830231 2005
44
Central cholecystokinin activity in irritable bowel syndrome, panic disorder, and healthy controls. 61 54
16046372 2005
45
Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects. 61 54
15939844 2005
46
The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder. 54 61
15953484 2005
47
Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. 61 54
15944741 2005
48
Association study of A2a adenosine receptor genetic polymorphism in panic disorder. 54 61
15774265 2005
49
Norepinephrine transporter (NET) promoter and 5'-UTR polymorphisms: association analysis in panic disorder. 54 61
15722184 2005
50
Epistatic interaction between the monoamine oxidase A and serotonin transporter genes in anorexia nervosa. 61 54
15523490 2005
51
Novel hypothesis for the cause of panic disorder via the neuroepithelial bodies in the lung. 61 54
15823715 2005
52
Effects of the cortisol synthesis inhibitor metyrapone on the response to carbon dioxide challenge in panic disorder. 61 54
16001448 2005
53
Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. 54 61
15706463 2005
54
Panic induction with cholecystokinin-tetrapeptide (CCK-4) Increases plasma concentrations of the neuroactive steroid 3alpha, 5alpha tetrahydrodeoxycorticosterone (3alpha, 5alpha-THDOC) in healthy volunteers. 61 54
15467707 2005
55
NAG level differences in panic disorder and agoraphobia. 61 54
16076427 2005
56
Is premenstrual dysphoria a variant of panic disorder? A review. 61 54
15533279 2004
57
Reduced brain serotonin transporter binding in patients with panic disorder. 54 61
15598551 2004
58
5-HT1A receptors, gene repression, and depression: guilt by association. 54 61
15534042 2004
59
Metyrapone tests in patients with panic disorder. 61 54
15576069 2004
60
Focus on The 5-HT1A receptor: emerging role of a gene regulatory variant in psychopathology and pharmacogenetics. 61 54
15683551 2004
61
Lack of relationship between CO2 reactivity and serotonin transporter gene regulatory region polymorphism in panic disorder. 54 61
15274038 2004
62
The association between panic disorder and the L/L genotype of catechol-O-methyltransferase. 54 61
15203287 2004
63
[Neurobiology and pharmacotherapy of social phobia]. 61 54
15538306 2004
64
Serotonin-mediated phosphorylation of extracellular regulated kinases in platelets of patients with panic disorder versus controls. 61 54
15016478 2004
65
Association of the functional V158M catechol-O-methyl-transferase polymorphism with panic disorder in women. 61 54
15009906 2004
66
Sensitivity to cholecystokinin-tetrapeptide in major depression. 61 54
15207943 2004
67
Association of a functional 1019C>G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia. 54 61
14984628 2004
68
Association of cholecystokinin-A receptor gene polymorphisms and panic disorder in Japanese. 54 61
15108185 2004
69
Cholecystokinin- and cholecystokinin-B-receptor gene polymorphisms in panic disorder. 61 54
15354400 2004
70
Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder. 54 61
15390214 2004
71
Stress responsive neurohormones in depression and anxiety. 54 61
14677081 2003
72
[Significance of GABAA receptors for the pathophysiology and therapy of panic disorders]. 54 61
12861364 2003
73
Association analysis of MAOA and COMT with neuroticism assessed by peers. 61 54
12815746 2003
74
Positive association between panic disorder and polymorphism of the serotonin 2A receptor gene. 61 54
12759158 2003
75
Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. 61 54
12700707 2003
76
Transcriptional activities of cholecystokinin promoter haplotypes and their relevance to panic disorder susceptibility. 61 54
12627463 2003
77
Association between the CCK-A receptor gene and panic disorder. 54 61
12627462 2003
78
Plasma gamma-amino-butyric acid (GABA) levels in cholecystokinine-tetrapeptide (CCK-4) induced anxiety. 61 54
12658378 2003
79
Effects of acute cholecystokinin infusion on hemispheric EEG asymmetry and coherence in healthy volunteers. 61 54
12551742 2003
80
Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression. 61 54
12555227 2003
81
Norepinephrine transporter gene (NET) variants in patients with panic disorder. 54 61
12401556 2002
82
Catechol O-methyltransferase genetic polymorphism in panic disorder. 61 54
12359690 2002
83
Acute cholecystokinin effects on event-related potentials in healthy volunteers. 54 61
12404673 2002
84
The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers. 61 54
12007753 2002
85
Evidence for a susceptibility locus for panic disorder near the catechol-O-methyltransferase gene on chromosome 22. 54 61
11950461 2002
86
Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. 61 54
11772685 2002
87
Association studies of the CT repeat polymorphism in the 5' upstream region of the cholecystokinin B receptor gene with panic disorder and schizophrenia in Japanese subjects. 61 54
11803530 2001
88
Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. 61 54
11682253 2001
89
Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder. 61 54
11532742 2001
90
Opposite effects of nefazodone in two human models of anxiety. 54 61
11498723 2001
91
Identification of a compound short tandem repeat stretch in the 5'-upstream region of the cholecystokinin gene, and its association with panic disorder but not with schizophrenia. 61 54
11443535 2001
92
Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy. 54 61
11444684 2001
93
Alexithymia in DSM-IV disorder: comparative evaluation of somatoform disorder, panic disorder, obsessive-compulsive disorder, and depression. 61 54
11351112 2001
94
Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. 61 54
11296098 2001
95
Association studies of the cholecystokinin B receptor and A2a adenosine receptor genes in panic disorder. 54 61
11515749 2001
96
No association or linkage between polymorphisms in the genes encoding cholecystokinin and the cholecystokinin B receptor and panic disorder. 54 61
11244486 2001
97
Cholecystokinin and panic disorder: past and future clinical research strategies. 54 61
11713976 2001
98
Management of treatment-refractory panic disorder. 61 54
12397890 2001
99
Increased anxiety behavior in OLETF rats without cholecystokinin-A receptor. 61 54
11179844 2000
100
Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. 54 61
11121185 2000
101
Cholecystokinin and panic disorder--three unsettled questions. 54 61
11033055 2000
102
Polymorphic MAO-A and 5-HT-transporter genes: analysis of interactions in panic disorder. 61 54
12607224 2000
103
Function of the C-36 to T polymorphism in the human cholecystokinin gene promoter. 54 61
10889557 2000
104
Investigation of dopamine receptor (DRD4) and dopamine transporter (DAT) polymorphisms for genetic linkage or association to panic disorder. 61 54
10898909 2000
105
Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. 61 54
10870873 2000
106
Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. 61 54
10693152 2000
107
SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. 61 54
10664825 2000
108
Effects of natriuretic peptides upon hypothalamo-pituitary-adrenocortical system activity and anxiety behaviour. 54 61
10768826 2000
109
Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. 54 61
10494457 1999
110
[Neuropharmacological and genetic study of panic disorder]. 61 54
10495983 1999
111
Investigation of cholecystokinin system genes in panic disorder. 54 61
10395221 1999
112
Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. 61 54
10072430 1999
113
Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses. 54 61
10212068 1999
114
Lack of genetic linkage or association between a functional serotonin transporter polymorphism and panic disorder. 54 61
10335545 1999
115
No coding variant of the tryptophan hydroxylase gene detected in seasonal affective disorder, obsessive-compulsive disorder, anorexia nervosa, and alcoholism. 61 54
10088048 1999
116
Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder. 54 61
10023509 1999
117
Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. 61 54
9885797 1999
118
The platelet intracellular calcium response to serotonin and thrombin in patients with panic disorder. 61 54
10082235 1999
119
The 5-HT1A receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats. 54 61
10475723 1999
120
Electrophysiological evidence for an inverse benzodiazepine receptor agonist in panic disorder. 54 61
10094233 1999
121
Experimental pathophysiology of panic. 54 61
9859852 1998
122
An association of NAG levels and a mutation of the CCK gene in panic disorder patients. 61 54
9754694 1998
123
Possible association of a cholecystokinin promotor polymorphism (CCK-36CT) with panic disorder. 61 54
9603610 1998
124
Effect of flumazenil in lactate-sensitive patients with panic disorder. 61 54
9585710 1998
125
Effect of aging on cholecystokinin-induced panic. 61 54
9464213 1998
126
Increased benzodiazepine receptor density in the prefrontal cortex in patients with panic disorder. 61 54
9928900 1998
127
Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease. 61 54
9491818 1998
128
Neurobiology of panic disorder. 54 61
9483472 1998
129
Brain mechanisms of social anxiety disorder. 61 54
9811424 1998
130
Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. 54 61
9397424 1997
131
Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. 61 54
9401314 1997
132
Benzodiazepine receptor uptake in a patient with panic disorder after citalopram treatment. 61 54
9359124 1997
133
An association study between a transcriptional polymorphism in the serotonin transporter gene and panic disorder in a Japanese population. 61 54
9413883 1997
134
Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder. 54 61
9335081 1997
135
The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. 61 54
9084062 1997
136
Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. 54 61
9085405 1997
137
Functional promoter polymorphism of the human serotonin transporter: lack of association with panic disorder. 54 61
9264139 1997
138
Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. 54 61
8988798 1997
139
Emotional and cognitive factors connected with response to cholecystokinin tetrapeptide in healthy volunteers. 61 54
9061804 1997
140
Inositol treatment of autism. 54 61
9203092 1997
141
[From inducers of panic attack to neurobiology of panic disorder]. 61 54
9138945 1996
142
Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. 61 54
8888384 1996
143
The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder. 54 61
8880078 1996
144
Pentagastrin has panic-inducing properties in obsessive compulsive disorder. 54 61
8878350 1996
145
Missense mutation of the cholecystokinin B receptor gene: lack of association with panic disorder. 54 61
8837709 1996
146
Influence of personality on behavioral response to cholecystokinin-tetrapeptide in patients with panic disorder. 61 54
8771610 1996
147
Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. 61 54
8634010 1996
148
CCK-4-induced calcium mobilization in T cells is enhanced in panic disorder. 61 54
8627317 1996
149
Association of levels of N-acetyl-beta-glucosaminidase with severity of psychiatric symptoms in panic disorder. 61 54
8723309 1996
150
Hypothalamic-pituitary-adrenal axis activity in panic disorder: effects of alprazolam on 24 h secretion of adrenocorticotropin and cortisol. 61 54
8816303 1996
151
Selective blockade of cholecystokinin type B receptors with L-365,260 does not impair gallbladder contraction in normal humans. 61 54
8633511 1996
152
Two faces of cholecystokinin: anxiety and schizophrenia. 61 54
8737954 1996
153
Provocative agents in panic disorder. 61 54
7482384 1995
154
Abnormal regional benzodiazepine receptor uptake in the prefrontal cortex in patients with panic disorder. 61 54
7624108 1995
155
A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. 54 61
7786960 1995
156
Panic disorder. Pathophysiology and drug treatment. 54 61
7774510 1995
157
Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. 54 61
7838898 1995
158
On the significance of cholecystokinin receptors in panic disorder. 61 54
7863014 1994
159
Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology. 61 54
7524696 1994
160
Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses. 54 61
7948449 1994
161
The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. 54 61
8192551 1994
162
Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. 61 54
7855203 1994
163
The cholecystokinin hypothesis of anxiety and panic disorder. 61 54
8185169 1994
164
Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. 61 54
8296900 1994
165
Neuropeptides and anxiety: focus on cholecystokinin. 54 61
8313613 1994
166
Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. A preliminary report. 61 54
7918702 1994
167
Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers. 54 61
9160584 1994
168
Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findings. 54 61
9160564 1994
169
Changes in peripheral benzodiazepine receptors in patients with panic disorder and obsessive-compulsive disorder. 54 61
8127425 1994
170
Lymphocyte cholecystokinin concentrations in panic disorder. 54 61
8317587 1993
171
Blunted growth hormone responses to growth hormone-releasing factor and to clonidine in panic disorder. 54 61
8422091 1993
172
Prolactin response to dl-fenfluramine in panic disorder. 54 61
8416044 1993
173
Reversible monoamine oxidase-A inhibitors in panic disorder. 54 61
8313401 1993
174
A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder. 54 61
1467375 1992
175
Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A. 61 54
1494591 1992
176
CSF diazepam-binding inhibitor concentrations in panic disorder. 61 54
1333825 1992
177
Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. 54 61
1609879 1992
178
CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. 54 61
1575262 1992
179
Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. 54 61
1610485 1992
180
5-HT1A receptor-effector system responsivity in panic disorder. 54 61
1346719 1992
181
Peripheral-type benzodiazepine receptors in anxiety disorders. 61 54
1686517 1991
182
Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. 54 61
2069490 1991
183
Benzodiazepine receptor sensitivity in panic disorder. 54 61
1671933 1991
184
Endocrine, cardiovascular, and behavioral effects of intravenous protirelin in patients with panic disorder. 61 54
1899183 1991
185
Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. 54 61
1850142 1991
186
Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. 54 61
2171449 1990
187
Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder. 54 61
2139731 1990
188
Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. 61 54
2180549 1990
189
Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. 61 54
1697419 1990
190
Thyrotropin and prolactin responses to protirelin (TRH) prior to and during chronic imipramine treatment in patients with panic disorder. 54 61
2129312 1990
191
White matter connectivity differences between treatment responders and non-responders in patients with panic disorder. 61
31539689 2020
192
Effects of the adjunctive treatment of antidepressants with opiorphin on a panic-like defensive response in rats. 61
31568834 2020
193
Measuring strengths and weaknesses in dimensional psychiatry. 61
31423596 2020
194
Differential effects of alliance and techniques on Panic-Specific Reflective Function and misinterpretation of bodily sensations in two treatments for panic. 61
30821630 2020
195
The amygdala differentially regulates defensive behaviors evoked by CO2. 61
31536735 2020
196
Comorbidity with more anxiety disorders associated with a poorer prognosis persisting at the 10-year follow-up among patients with major depressive disorder. 61
31493646 2020
197
Association between History of Concussion and Substance Use Is Mediated by Mood Disorders. 61
31359826 2020
198
Social phobia moderates the outcome in the EVIDENT study: A randomized controlled trial on an Internet-based psychological intervention for mild to moderate depressive symptoms. 61
31682137 2020
199
Resting-state causal connectivity of the bed nucleus of the stria terminalis in panic disorder. 61
31833015 2019
200
Longitudinal association between panic disorder and health care costs in older adults. 61
31609044 2019
201
Posttraumatic stress, panic disorder, violence, and recidivism among local jail detainees. 61
31532342 2019
202
Determinants of treatment of mental disorders in Lebanon: barriers to treatment and changing patterns of service use. 61
30101735 2019
203
Randomized clinical trial of capnometry-assisted respiratory training in veterans with posttraumatic stress disorder hyperarousal. 61
31804108 2019
204
Comorbidity and polypharmacy among women living with HIV in British Columbia. 61
31764097 2019
205
Predicting treatment failure in regular care Internet-Delivered Cognitive Behavior Therapy for depression and anxiety using only weekly symptom measures. 61
31829635 2019
206
Increased epoch-to-epoch parasympathetic cardiac regulation in participants with posttraumatic stress disorder compared to those with panic disorder and control participants. 61
31593854 2019
207
Effect of CBT on Biased Semantic Network in Panic Disorder: A Multicenter fMRI Study Using Semantic Priming. 61
31838872 2019
208
A randomized, single-dose, two-sequence, two-period, crossover study to assess the bioequivalence between two formulations of clonazepam tablet in healthy subjects. 61
31702402 2019
209
eHealth-supported case management for patients with panic disorder or depression in primary care: Study protocol for a cRCT (PREMA). 61
31791389 2019
210
Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: Subgroup analysis of the randomized, active- and placebo-controlled EAGLES trial. 61
31850603 2019
211
Exposure-induced changes of plasma metabolome and gene expression in patients with panic disorder. 61
31374578 2019
212
Trait anger and anger attacks in relation to depressive and anxiety disorders. 61
31450135 2019
213
Modifiable risk and protective factors for anxiety disorders among adults: A systematic review. 61
31839417 2019
214
Affective temperaments (TEMPS-A) in panic disorder and healthy probands - genetic modulation by 5-HTT variation. 61
31852378 2019
215
Characterizing the nature of emotional-associative learning deficits in panic disorder: An fMRI study on fear conditioning, extinction training and recall. 61
30497840 2019
216
Ratio of plasma BDNF to leptin levels are associated with treatment response in major depressive disorder but not in panic disorder: A 12-week follow-up study. 61
31465895 2019
217
Food Insecurity Is Associated With Poorer Mental Health and Sleep Outcomes in Young Adults. 61
31587956 2019
218
In-session emotional expression predicts symptomatic and panic-specific reflective functioning improvements in panic-focused psychodynamic psychotherapy. 61
30869969 2019
219
Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. 61
31470029 2019
220
The DNA methylome in panic disorder: a case-control and longitudinal psychotherapy-epigenetic study. 61
31754096 2019
221
Client resistance predicts outcomes in cognitive-behavioral therapy for panic disorder. 61
30049247 2019
222
Utilization of learned skills in cognitive behavioural therapy for panic disorder. 61
31122300 2019
223
Focus is key: Panic-focused interpretations are associated with symptomatic improvement in panic-focused psychodynamic psychotherapy. 61
29667870 2019
224
Panic attack provocation in panic disorder patients with a computer simulation. 61
31786029 2019
225
Anxiety comorbidities in patients with major depressive disorder: the role of attachment. 61
31464550 2019
226
The effectiveness of mindfulness-based cognitive therapy in patients with anxiety disorders in secondary care settings: a randomized controlled trial. 61
31774604 2019
227
Clinical features and patterns of psychopharmacological prescription in bipolar patients with vs without anxiety disorders at onset. 61
31733039 2019
228
Effectiveness of trauma-focused cognitive behavioral therapy for terrorism victims with very long-term emotional disorders. 61
31634084 2019
229
Couples in arms: Marital distress, psychopathology, and suicidal ideation in active-duty Army personnel. 61
31750678 2019
230
Psychiatric disorders associated with acquired brain pathology. 61
30183352 2019
231
Genome-wide association study of panic disorder reveals genetic overlap with neuroticism and depression. 61
31712720 2019
232
A Hierarchical Integration of Normal and Abnormal Personality Dimensions: Structure and Predictive Validity in a Heterogeneous Sample of Psychiatric Outpatients. 61
31729250 2019
233
Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment. 61
31304840 2019
234
Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Systematic Review and Meta-analysis. 61
31758858 2019
235
Prognosis Prediction Using Therapeutic Agreement of Video Conference-Delivered Cognitive Behavioral Therapy: Retrospective Secondary Analysis of a Single-Arm Pilot Trial. 61
31730037 2019
236
The impact of methodological and measurement factors on transdiagnostic associations with intolerance of uncertainty: A meta-analysis. 61
31678816 2019
237
Relationships between depressive symptoms and panic disorder symptoms during guided internet-delivered cognitive behavior therapy for panic disorder. 61
31373520 2019
238
PET imaging on neurofunctional changes after optogenetic stimulation in a rat model of panic disorder. 61
31321611 2019
239
Development of a very brief scale for detecting and measuring panic disorder using two items from the Panic Disorder Severity Scale-Self Report. 61
31349178 2019
240
Association of rs7688285 allelic variation coding for GLRB with fear reactivity and exposure-based therapy in patients with panic disorder and agoraphobia. 61
31444036 2019
241
Collaborative care vs consultation liaison for depression and anxiety disorders in general practice: study protocol for two randomized controlled trials (the Danish Collabri Flex trials). 61
31653228 2019
242
Anxiety disorders anticipate the diagnosis of bipolar disorder in comorbid patients: Findings from an Italian tertiary clinic. 61
31302527 2019
243
Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis. 61
31646432 2019
244
Hypermethylation of the serotonin transporter gene promoter in panic disorder-Epigenetic imprint of comorbid depression? 61
31353282 2019
245
Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: A 12-week follow-up study. 61
31669792 2019
246
Identification and medical utilization of newly diagnosed panic disorder: A Nationwide case-control study. 61
31450125 2019
247
Validation of the Recent Life Changes Questionnaire (RLCQ) for stress measurement among adults residing in urban communities in Pakistan. 61
31639054 2019
248
Differences in anxiety sensitivity factors between anxiety and depressive disorders. 61
31344315 2019
249
Reassurance seeking in the anxiety disorders and OCD: Construct validation, clinical correlates and CBT treatment response. 61
31430610 2019
250
The relationship between obsessive-compulsive disorder and anxiety disorders: A question of diagnostic boundaries or simply severity of symptoms? 61
31421287 2019
251
Duration of untreated illness in a cross-diagnostic sample of obsessive-compulsive disorder, panic disorder, and social anxiety disorder. 61
30419984 2019
252
Electroretinography in psychiatry: A systematic literature review. 61
31553929 2019
253
Risk factors for suicidality in patients with panic disorder: A systematic review and meta-analysis. 61
31376408 2019
254
A lack of differentiation in amygdala responses to fearful expression intensity in panic disorder patients. 61
31357097 2019
255
Effect of fluoxetine and psychotherapy on heart rate variability in children and adolescents diagnosed with panic disorder: 24-hour Holter monitoring study before and after treatment. 61
31483315 2019
256
Combining Xenon Inhalation With Trauma Memory Reactivation to Reduce Symptoms of Posttraumatic Stress Disorder: Case Report, Justification of Approach, and Review of the Literature. 61
31538751 2019
257
[Dental and oral surgical treatment of the mentally retarded in Hungary: the situation in the past, currently and hopes for the future]. 61
31448643 2019
258
Dysfunctional cognition and self-efficacy as mediators of symptom change in exposure therapy for agoraphobia - Systematic review and meta-analysis. 61
31374484 2019
259
Acute Carbon Monoxide Poisoning Secondary to Cigarette Smoking in a 40-Year-Old Man: A Case Report. 61
31348564 2019
260
Importance of knowledge in the behavioural treatment of panic disorder. 61
30935431 2019
261
Accuracy of Anxiety Disorder Not Otherwise Specified Diagnosis in Older Veterans. 61
31505520 2019
262
Startle during threat longitudinally predicts functional impairment independent of DSM diagnoses. 61
30853118 2019
263
Agitated depression in bipolar disorder. 61
31004555 2019
264
Postural Orthostatic Tachycardia Syndrome Is Associated With Elevated G-Protein Coupled Receptor Autoantibodies. 61
31495251 2019
265
Foot shock stress generates persistent widespread hypersensitivity and anhedonic behavior in an anxiety-prone strain of mice. 61
31568043 2019
266
Manualized single-session behavior treatment with self-help manual for panic disorder with or without agoraphobia. 61
31510890 2019
267
Mood instability contributes to impulsivity, non-suicidal self-injury, and binge eating/purging in people with anxiety disorders. 61
30003688 2019
268
Are claims of non-inferiority of Internet and computer-based cognitive-behavioural therapy compared with in-person cognitive-behavioural therapy for adults with anxiety disorders supported by the evidence from head-to-head randomised controlled trials? A systematic review. 61
31339342 2019
269
Anxiety disorders and medical illness comorbidity and treatment implications. 61
31116127 2019
270
A systematic review of quantitative EEG as a possible biomarker in child psychiatric disorders. 61
31300243 2019
271
Bipolar disorder comorbidity in patients with obsessive-compulsive disorder: Prevalence and predictors. 61
31201983 2019
272
Developing and Validating a Computerized Adaptive Test to Measure Broad and Specific Factors of Internalizing in a Community Sample. 61
28467115 2019
273
Resilience and coping strategies in cognitive behavioral group therapy for patients with panic disorder. 61
31280790 2019
274
Cognitive-behavioral therapy effects on alerting network activity and effective connectivity in panic disorder. 61
30288559 2019
275
Comorbidity and polypharmacy among women living with HIV in British Columbia. 61
31449095 2019
276
Social Media Use Subgroups Differentially Predict Psychosocial Well-Being During Early Adolescence. 61
31256313 2019
277
Interoception, conditioning, and fear: The panic threesome. 61
31228272 2019
278
The Effect of Media Coverage of Celebrities with Panic Disorder on the Health Behaviors of the Public. 61
29565680 2019
279
Anxiolytic and panicolytic-like effects of environmental enrichment seem to be modulated by serotonin neurons located in the dorsal subnucleus of the dorsal raphe. 61
31220551 2019
280
Common and different neural markers in major depression and anxiety disorders: A pilot structural magnetic resonance imaging study. 61
31279954 2019
281
Associations between asthma trigger reports, mental health conditions, and asthma morbidity among world trade center rescue and recovery workers. 61
30073876 2019
282
In search of disorders: internalizing symptom networks in a large clinical sample. 61
30900257 2019
283
Psychopharmacology of Pediatric Anxiety Disorders: A Narrative Review. 61
31656713 2019
284
The characteristics of the comorbidity between social anxiety and separation anxiety disorders in adult patients. 61
31322453 2019
285
Prevalence, onset and course of anxiety disorders during pregnancy: A systematic review and meta analysis. 61
31129461 2019
286
Low high-density lipoprotein and psychopathology: A review. 61
31369659 2019
287
Associations of fatigue and sleep disturbance with nine common mental disorders. 61
31376877 2019
288
Trends and factors in antipsychotic use of outpatients with anxiety disorders in Taiwan, 2005-2013: A population-based study. 61
31077503 2019
289
A systematic review and meta-analysis of the Unified Protocol as a transdiagnostic emotion regulation based intervention. 61
31271848 2019
290
Brief Therapist-Guided Exposure Treatment of Panic Attacks: A Pilot Study. 61
29862830 2019
291
Internet-delivered cognitive behavioral therapy for panic disorder with or without agoraphobia: a systematic review and meta-analysis. 61
31303121 2019
292
Moderators and predictors of outcome in metacognitive and cognitive behavioural therapy for co-morbid anxiety disorders. 61
30811709 2019
293
Treatment of anxiety and mood comorbidities in cognitive-behavioral and psychodynamic therapies for panic disorder. 61
31015099 2019
294
Repeated Interoceptive Exposure in Individuals With High and Low Anxiety Sensitivity. 61
29690770 2019
295
[Development of virtual reality as an exposure technique]. 61
30715554 2019
296
Bidirectional Association between First-Episode Panic Disorder and Major Depressive Disorder in a Nationwide General Population Survey in Korea. 61
31269543 2019
297
Comorbidity of substance misuse with anxiety-related and depressive disorders: a genetically informative population study of 3 million individuals in Sweden. 61
31328718 2019
298
Internet Interventions for Adults with Anxiety and Mood Disorders: A Narrative Umbrella Review of Recent Meta-Analyses. 61
31096757 2019
299
Association study of SLC6A2 gene Thr99Ile variant (rs1805065) with athletic status in the Brazilian population. 61
31075414 2019
300
The Prevalence of Mitral Valve Prolapse in Panic Disorder: A Meta-Analysis. 61
30448200 2019
301
Discrepancies Between Nomenclature and Indications of Psychotropics. 61
29791934 2019
302
Elevated peripheral kynurenine/tryptophan ratio predicts poor short-term auditory memory in panic disorder patients. 61
30959226 2019
303
Mediators of Change in Capnometry Guided Respiratory Intervention for Panic Disorder. 61
30539503 2019
304
Incidence of panic disorder in patients with non-cardiac chest pain and panic attacks. 61
31250658 2019
305
Abnormal frontal generator during auditory sensory gating in panic disorder: An MEG study. 61
31014913 2019
306
A panel of miRNAs is involved in the effect of sertraline on panic disorder, as implicated by a microarray-based analysis. 61
30974330 2019
307
Increasing intentions to use mental health services among university students. Results of a pilot randomized controlled trial within the World Health Organization's World Mental Health International College Student Initiative. 61
30456814 2019
308
Nitric oxide in the dorsal periaqueductal gray mediates the panic-like escape response evoked by exposure to hypoxia. 61
30742862 2019
309
Select panicogenic drugs and stimuli induce consistent increases in tail skin flushes and decreases in core body temperature. 61
30480550 2019
310
Incongruence Between Implicit Attachment Schemes and Unconscious Attachment Representations. 61
31045952 2019
311
Blood, Sweat, and/or Tears: Comparing Nervios Symptom Descriptions in Honduras. 61
30612305 2019
312
Recruitment of central angiotensin II type 1 receptor associated neurocircuits in carbon dioxide associated fear. 61
30776402 2019
313
Vestibular function in panic disorder patients: a vestibular-evoked myogenic potentials and video head impulse test study. 61
30923888 2019
314
Transcranial magnetic stimulation in anxiety and trauma-related disorders: A systematic review and meta-analysis. 61
31066227 2019
315
Explaining the association between anxiety disorders and alcohol use disorder: A twin study. 61
30838764 2019
316
The unique and conditional effects of interoceptive exposure in the treatment of anxiety: A functional analysis. 61
30579624 2019
317
Major Depressive Disorder Is Associated with Impaired Interoceptive Accuracy: A Systematic Review. 61
31174264 2019
318
[Panic disorder and agoraphobia in general practice: Advantages and pitfalls of a practice team-supported exposure training from the general practitioner's perspective - a qualitative study]. 61
31176641 2019
319
A comparison of DSM-5 and DSM-IV agoraphobia in the World Mental Health Surveys. 61
30726581 2019
320
Comparing Treatment Acceptability and 12-Month Cessation Rates in Response to Web-Based Smoking Interventions Among Smokers Who Do and Do Not Screen Positive for Affective Disorders: Secondary Analysis. 61
31219052 2019
321
Risk and protective factors for anxiety and obsessive-compulsive disorders: an umbrella review of systematic reviews and meta-analyses. 61
31172897 2019
322
Associations of child and adolescent anxiety with later alcohol use and disorders: a systematic review and meta-analysis of prospective cohort studies. 61
30891835 2019
323
Psychiatric epidemiology and disaster exposure in Australia. 61
28950925 2019
324
Do patients with ICD who report anxiety symptoms on Hospital Anxiety and Depression Scale suffer from anxiety? 61
30955912 2019
325
Allergic rhinitis increases the risk of incident panic disorder among young individuals: A nationwide population-based cohort study in Taiwan. 61
30981057 2019
326
Mental disorder comorbidity and suicidal thoughts and behaviors in the World Health Organization World Mental Health Surveys International College Student initiative. 61
30450753 2019
327
Public, health professional and legislator perspectives on the concept of psychiatric disease: a population-based survey. 61
31167856 2019
328
GABAA/benzodiazepine receptors in the dorsal periaqueductal gray mediate the panicolytic but not the anxiolytic effect of alprazolam in rats. 61
30768992 2019
329
Sex- and Gender-Stratified Risks of Psychological Factors for Incident Ischemic Heart Disease: Systematic Review and Meta-Analysis. 61
31030598 2019
330
Emotion Regulation Strategies in Cognitive Behavioral Therapy for Panic Disorder. 61
31030881 2019
331
Symptom trajectories in patients with panic disorder in a primary care intervention: Results from a randomized controlled trial (PARADISE). 61
31073189 2019
332
Heightened sensitivity to panic-related sounds with reduced sensitivity to neutral sounds in preattentive processing among panic patients. 61
30870769 2019
333
Video-Delivered Relaxation Intervention Reduces Late-Life Anxiety: A Pilot Randomized Controlled Trial. 61
30765288 2019
334
Exploring characteristics associated with first benzodiazepine prescription in patients with affective disorders and related diagnoses. 61
31044486 2019
335
Treatment of Common Mental Disorders in the United States: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. 61
31141319 2019
336
Heart rate variability in patients with agoraphobia with or without panic disorder remains stable during CBT but increases following in-vivo exposure. 61
30875662 2019
337
Pharmacological Therapy in Panic Disorder: Current Guidelines and Novel Drugs Discovery for Treatment-resistant Patient. 61
30905115 2019
338
Relation between cognitive and behavioral strategies and future change in common mental health problems across 18 years. 61
31045412 2019
339
Physical activity is indirectly associated with pain in college women through associations with somatization and panic disorder symptoms: a cross-sectional study. 61
30905543 2019
340
External validation of the International Risk Prediction Algorithm for the onset of generalized anxiety and/or panic syndromes (The Predict A) in the US general population. 61
30974236 2019
341
Time course of panic disorder and posttraumatic stress disorder onsets. 61
30003310 2019
342
Insensitivity of auditory mismatch negativity to classical fear conditioning and extinction in healthy humans. 61
30817683 2019
343
Depression and Anxiety Disorders: Benefits of Exercise, Yoga, and Meditation. 61
31083878 2019
344
Measuring treatment outcome in patients with anxiety disorders: A comparison of the responsiveness of generic and disorder-specific instruments. 61
30986658 2019
345
Relationship between craving and impulsivity in patients with alcohol dependence with or without dual disorders in an outpatient treatment center: a descriptive study. 61
31233207 2019
346
Allergies, asthma, and psychopathology in a nationally-representative US sample. 61
30921596 2019
347
Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. 61
31072313 2019
348
The neural markers of MRI to differentiate depression and panic disorder. 61
29705713 2019
349
N-methyl-D-aspartate Partial Agonist Enhanced Intensive Cognitive-Behavioral Therapy of Panic Disorder in Adolescents. 61
30078111 2019
350
Feeling and body investigators (FBI): ARFID division-An acceptance-based interoceptive exposure treatment for children with ARFID. 61
30597590 2019
351
Hypothalamic endocannabinoid signalling modulates aversive responses related to panic attacks. 61
30677422 2019
352
NO in the dPAG modulates panic-like responses and ASIC1a expression in the prefrontal cortex and hippocampus in mice. 61
30770101 2019
353
The complex interplay between gastrointestinal and psychiatric symptoms in irritable bowel syndrome: A longitudinal assessment. 61
29971822 2019
354
Improvement in adult anxious and avoidant attachment during cognitive behavioral therapy for panic disorder. 61
28826378 2019
355
The role of therapist and patient in-session behavior for treatment outcome in exposure-based cognitive behavioral therapy for panic disorder with agoraphobia. 61
30597535 2019
356
Will the RANZCP clinical practice guidelines for the treatment of anxiety disorders assist in making adequate treatment decisions for panic disorder? 61
30518224 2019
357
Neuroimaging findings as predictors of treatment outcome of psychotherapy in anxiety disorders. 61
29627509 2019
358
The effects of trans-cranial direct current stimulation intervention on fear: A systematic review of literature. 61
30660476 2019
359
NOMOPHOBIA: NO MObile PHone PhoBIA. 61
31143710 2019
360
Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users. 61
30738930 2019
361
The BDNF Val66Met gene polymorphism is associated with increased alexithymic and anticipatory anxiety in patients with panic disorder. 61
30269521 2019
362
Can sleep disturbance be a cue of mood spectrum comorbidity? A preliminary study in panic disorder. 61
30971322 2019
363
Psychiatric diagnosis in primary care patients with increased depressive symptoms. 61
30929594 2019
364
Psychiatric Disorders and Alcohol Consumption Among Low-Income African Americans:Gender Differences. 61
31003459 2019
365
The Relationship Between Epilepsy and Anxiety Disorders. 61
31037466 2019
366
Posttraumatic Stress Disorder and Psychiatric Comorbidity among Adolescent Earthquake Survivors: a Longitudinal Cohort Study. 61
30167997 2019
367
Depressive Symptom Severity in Individuals With Epilepsy and Recent Health Complications. 61
30865078 2019
368
Intolerance of uncertainty and responsibility for harm predict nocturnal panic attacks. 61
30640055 2019
369
The Depression Treatment Cascade: Disparities by Alcohol Use, Drug Use, and Panic Symptoms Among Patients in Routine HIV Care in the United States. 61
30288684 2019
370
Trauma-Focused Psychodynamic Psychotherapy of a Patient With PTSD in a Veterans Affairs Setting. 61
30786735 2019
371
Effects of Cytochrome P450 2C19 Genetic Polymorphisms on Responses to Escitalopram and Levels of Brain-Derived Neurotrophic Factor in Patients With Panic Disorder. 61
30742590 2019
372
The Prevalence of patients with panic attacks (PAs) and panic disorder (PD) visiting Emergency Departments of the Verona Hospital. 61
30714607 2019
373
High-Intensity Interval Training in Panic Disorder Patients: A Pilot Study. 61
30724830 2019
374
Panic Disorder in Primary Care. 61
30995952 2019
375
DNA methylation of FKBP5 and response to exposure-based psychological therapy. 61
30334356 2019
376
Benzodiazepines versus placebo for panic disorder in adults. 61
30921478 2019
377
Screening for depressive and anxiety disorders among adolescents in Indonesia: Formal validation of the centre for epidemiologic studies depression scale - revised and the Kessler psychological distress scale. 61
30583144 2019
378
Reciprocal associations between screen time and emotional disorder symptoms during adolescence. 61
30733913 2019
379
Associations of plasma testosterone with clinical manifestations in acute panic disorder. 61
30471570 2019
380
The German Adaptation of the Therapist Beliefs about Exposure Scale: a Validation Study among Licensed Cognitive Behavioural Therapists in Germany. 61
29897024 2019
381
Does prior traumatization affect the treatment outcome of CBT for panic disorder? The potential role of the MAOA gene and depression symptoms. 61
28712090 2019
382
Transgenerational Transmission of Trauma: Psychiatric Evaluation of Offspring of Former "Comfort Women," Survivors of the Japanese Military Sexual Slavery during World War II. 61
30934192 2019
383
Psychometric Properties of 7- and 30-Day Versions of the PROMIS Emotional Distress Item Banks in an Australian Adult Sample. 61
28052687 2019
384
Heart rate variability for treatment response between patients with major depressive disorder versus panic disorder: A 12-week follow-up study. 61
30583140 2019
385
Digitally Delivered Psychological Interventions for Anxiety Disorders: a Comprehensive Review. 61
30488330 2019
386
Psychological Disorder Identifying Method Based on Emotion Perception over Social Networks. 61
30884824 2019
387
The Revised Child Anxiety and Depression Scales (RCADS): Psychometric Evaluation in Children Evaluated for ADHD. 61
30930533 2019
388
Visuo-Haptic-Based Multimodal Feedback Virtual Reality Solution to Improve Anxiety Symptoms: A Proof-of-Concept Study. 61
30808124 2019
389
Association of generalized anxiety symptoms and panic with health care costs in older age-Results from the ESTHER cohort study. 61
30562680 2019
390
Anterior hippocampal volume predicts affect-focused psychotherapy outcome. 61
30773148 2019
391
Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes. 61
30718541 2019
392
Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial. 61
30760241 2019
393
Brain activation during disorder-related script-driven imagery in panic disorder: a pilot study. 61
30787382 2019
394
Lifetime experience of multiple common mental disorders and 19-year mortality: results from a Canadian population-based cohort. 61
30712520 2019
395
Contribution of traumatic deployment experiences to the burden of mental health problems in Canadian Armed Forces personnel: exploration of population attributable fractions. 61
30027449 2019
396
The impact of depressive comorbidity on neural plasticity following cognitive-behavioral therapy in panic disorder with agoraphobia. 61
30428445 2019
397
Prior Mental Disorders and Lifetime Suicidal Behaviors Among US Army Soldiers in the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). 61
28926674 2019
398
A case of mistaken diagnoses: diagnostic and management challenges in a case of adult autism spectrum disorder. 61
30761975 2019
399
Associations between schizophrenia genetic risk, anxiety disorders and manic/hypomanic episode in a longitudinal population cohort study. 61
30472973 2019
400
Affect and worry during a checking episode: A comparison of individuals with symptoms of obsessive-compulsive disorder, anorexia nervosa, bulimia nervosa, body dysmorphic disorder, illness anxiety disorder, and panic disorder. 61
30599438 2019
401
Prevalence of mood and anxiety disorders during pregnancy: A case-control study with a large sample size. 61
30597383 2019
402
Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018. 61
30696238 2019
403
Reduced Sensitivity to Non-Fear-Related Stimulus Changes in Panic Disorder. 61
30947222 2019
404
Diagnostic Utility of Sodium Lactate Infusion and CO2-35% Inhalation for Panic Disorder. 61
30982042 2019
405
Internet-Delivered Psychological Treatment Options for Panic Disorder: A Review on Their Efficacy and Acceptability. 61
30122031 2019
406
Fear Network Model in Panic Disorder: The Past and the Future. 61
30176707 2019
407
The Experience Sampling Method-Evaluation of treatment effect of escitalopram in IBS with comorbid panic disorder. 61
30460734 2019
408
[A Meta-Analysis of Efficacy of Carbon Dioxide Inhalation as a Challenge Test in Panic Disorder]. 61
31487375 2019
409
Comparison of Cortisol Stress Response in Patients with Panic Disorder, Cannabis-Induced Panic Disorder, and Healthy Controls. 61
30879013 2019
410
An Integrated Bio-psycho-social Approach to Psychiatric Disorders. 61
31705503 2019
411
The prevalence of panic disorder and its related factor in hospitalized patients with chest pain and normal angiography. 61
31008128 2019
412
Meta-Analysis of Neuropsychological Studies in Panic Disorder Patients: Evidence of Impaired Performance during the Emotional Stroop Task. 61
30970364 2019
413
Effect of single doses of pindolol and d-fenfluramine on flumazenil-induced anxiety in panic disorder patients. 61
29113874 2019
414
Clinical and Neurofunctional Substrates of Cognitive Behavioral Therapy on Secondary Social Anxiety Disorder in Primary Panic Disorder: A Longitudinal fMRI Study. 61
30368504 2019
415
Fluoxetine Modulates Spontaneous and Conditioned Behaviors to Carbon Dioxide (CO2) Inhalation and Alters Forebrain-Midbrain Neuronal Activation. 61
30439538 2019
416
The allocation of resources in the care for patients with panic disorder in Germany: an excess cost analysis informing policy and science. 61
31061640 2019
417
Association of NPSR1 gene variation and neural activity in patients with panic disorder and agoraphobia and healthy controls. 61
31734525 2019
418
Contextual Fear Conditioning and Fear Generalization in Individuals With Panic Attacks. 61
31379530 2019
419
Psychometric analysis of the Swedish panic disorder severity scale and its self-report version. 61
30636466 2019
420
Biological and Clinical Markers in Panic Disorder. 61
30184613 2019
421
Panic Disorder: Current Research and Management Approaches. 61
30696237 2019
422
A Novel Bio-Psychosocial-Behavioral Treatment Model of Panic Disorder. 61
30301303 2019
423
Panic Disorder and Chronic Caffeine Use: A Case-control Study. 61
31819760 2019
424
PDE4B gene polymorphism in Russian patients with panic disorder. 61
31663033 2019
425
More anxious than depressed: prevalence and correlates in a 15-nation study of anxiety disorders in people with type 2 diabetes mellitus. 61
31552386 2019
426
Epidemiology of Alcohol Use in Late Adolescence in Greece and Comorbidity with Depression and Other Common Mental Disorders. 61
31662906 2019
427
Ages at Onset of Anxiety and Depressive Disorders in Parkinson's Disease. 61
31117906 2019
428
The Effectiveness of Art Therapy for Anxiety in Adult Women: A Randomized Controlled Trial. 61
31191400 2019
429
Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment. 61
30873251 2019
430
Virtual reality exposure therapy for anxiety and related disorders: A meta-analysis of randomized controlled trials. 61
30287083 2019
431
Commentary on RANZCP clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. 61
30511582 2019
432
A systematic review on the therapeutic effectiveness of non-invasive brain stimulation for the treatment of anxiety disorders. 61
30543906 2019
433
Validity of the DSM-5 anxious distress specifier for major depressive disorder. 61
30311733 2019
434
Accuracy of online survey assessment of mental disorders and suicidal thoughts and behaviors in Spanish university students. Results of the WHO World Mental Health- International College Student initiative. 61
31487306 2019
435
Psychiatric comorbidity among alcohol-dependent individuals seeking treatment at the Alcohol Rehabilitation Unit, Stikland Hospital. 61
31049222 2019
436
The Prevalence of Specific Phobia by Age in an Italian Nationwide Survey: How Much Does it Affect the Quality of Life? 61
30972140 2019
437
Frequent attenders in general medical practice in Italy: a preliminary report on clinical variables related to low functioning. 61
30636877 2019
438
The ALPIM (Anxiety, Laxity, Pain, Immune, and Mood) Syndrome in Adolescents and Young Adults: A Cohort Study. 61
30791805 2019
439
Toward a personalized therapy for panic disorder: preliminary considerations from a work in progress. 61
31371969 2019
440
Serotonin and Norepinephrine Reuptake Inhibitors. 61
30838456 2019
441
Is There a Major Role for Undetected Autism Spectrum Disorder with Childhood Trauma in a Patient with a Diagnosis of Bipolar Disorder, Self-Injuring, and Multiple Comorbidities? 61
31249714 2019
442
Off-Target Effects of Clozapine-N-Oxide on the Chemosensory Reflex Are Masked by High Stress Levels. 61
31178741 2019
443
Quality of life, self-stigma, and coping strategies in patients with neurotic spectrum disorders: a cross-sectional study. 61
30787642 2019
444
[Adaptation and Reliability of the Structured Clinical Interview for DSM-5-Disorders - Clinician Version (SCID-5/CV) to the Turkish Language]. 61
31170307 2019
445
Examining the Hierarchical Influences of the Big-Five Dimensions and Anxiety Sensitivity on Anxiety Symptoms in Children. 61
31231271 2019
446
Systematic Review and Meta-Analysis: Anxiety and Depressive Disorders in Offspring of Parents With Anxiety Disorders. 61
30577938 2019
447
The Pattern of Psychiatric Morbidity in Chronic Obstructive Pulmonary Disease: A Cross-Sectional, Case-Control Study from a Tertiary Care Hospital in Kashmir, North India. 61
30765973 2019
448
Anxiety Disorders in Older Patients. 61
30806999 2019
449
Videoconferencing psychological therapy and anxiety: a systematic review. 61
30188992 2019
450
Prevalence and associated factors of comorbid anxiety disorders in late-life depression: findings from geriatric tertiary outpatient settings. 61
30662265 2019
451
[Prevalence of Depression and Anxiety Disorders and Their Relationship with Sexual Functions in Women Diagnosed with Lifelong Vaginismus]. 61
31170302 2019
452
Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder. 61
31749717 2019
453
Mental disorders and the risk of adult violent and psychological victimisation: a prospective, population-based study. 61
30651151 2019
454
Minocycline-induced transient depersonalization: A case report. 61
30719316 2019
455
Neuromyelitis optica spectrum disorder with increased aquaporin-4 microparticles prior to autoantibodies in cerebrospinal fluid: a case report. 61
30696485 2019
456
Comorbidity of developmental trauma disorder (DTD) and post-traumatic stress disorder: findings from the DTD field trial. 61
30728917 2019
457
Establishing US norms for the Adult ADHD Self-Report Scale (ASRS-v1.1) and characterising symptom burden among adults with self-reported ADHD. 61
30239073 2019
458
Evaluation of Heart Rate Variability in Drug Free Panic Disorder Patients. 61
30622395 2018
459
Empirical evidence of the effect of personality pathology on the outcome of panic disorder. 61
30316085 2018
460
Gray matter changes in panic disorder: A voxel-based meta-analysis and meta-analytic connectivity modeling. 61
30340800 2018
461
Salivary alpha-amylase and cortisol responsiveness to stress in first episode, drug-naïve patients with panic disorder. 61
29550536 2018
462
Epidemiology of panic attacks, panic disorder and the moderating role of age: Results from a population-based study. 61
30172214 2018
463
Does Personality Matter? Temperament and Character Dimensions in Panic Subtypes. 61
30622388 2018
464
[Negative emotions associated with cardiovascular diseases]. 61
30501523 2018
465
Do Youth with Separation Anxiety Disorder Differ in Anxiety Sensitivity From Youth with Other Anxiety Disorders? 61
29666976 2018
466
Non-cardiac chest pain: a 2018 update. 61
29642692 2018
467
The Relationship Between Obsessive Belief Level and Cognitive Flexibility in Patients with Obsessive Compulsive Disorder. 61
30622397 2018
468
Internet-Based Cognitive Behavioral Therapy With Real-Time Therapist Support via Videoconference for Patients With Obsessive-Compulsive Disorder, Panic Disorder, and Social Anxiety Disorder: Pilot Single-Arm Trial. 61
30559094 2018
469
Neonatal outcomes in pregnant women with untreated and treated panic disorder. 61
30326358 2018
470
Cortical thickness reductions in the middle frontal cortex in patients with panic disorder. 61
30077161 2018
471
Treatment engagement in the early phase of cognitive-behavior therapy for panic disorder: A grounded theory analysis of patient experience. 61
27846780 2018
472
Hemodynamic characteristics of postural hyperventilation: POTS with hyperventilation versus panic versus voluntary hyperventilation. 61
30138078 2018
473
Mechanism of nitric oxide and acid-sensing ion channel 1a modulation of panic-like behaviour in the dorsal periaqueductal grey of the mouse. 61
29953907 2018
474
The interplay between experiential states in first generation schema therapy of Cluster C personality problems: A network approach. 61
30003609 2018
475
Dissemination of exposure in the treatment of anxiety disorders and post-traumatic stress disorder among German cognitive behavioural therapists. 61
30118184 2018
476
Efficacy and cost-effectiveness of therapist-guided internet cognitive behavioural therapy for paediatric anxiety disorders: a single-centre, single-blind, randomised controlled trial. 61
30241993 2018
477
Interplay between RGS2 and childhood adversities in predicting anxiety and depressive disorders: Findings from a general population sample. 61
30107643 2018
478
The impact of fibromyalgia syndrome and the role of comorbidity with mood and post-traumatic stress disorder in worsening the quality of life. 61
30146928 2018
479
The clinical correlates of comorbid anxiety symptoms and syndromal anxiety in patients with major depressive disorder. 61
30170282 2018
480
The association between HIV clinical disease severity and psychiatric disorders as seen in Western Romania. 61
29592527 2018
481
Screening for childhood anxiety: A meta-analysis of the screen for child anxiety related emotional disorders. 61
30081293 2018
482
Psychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis. 61
30066285 2018
483
Association between binge eating disorder and psychiatric comorbidity profiles in patients with obesity seeking bariatric surgery. 61
30253268 2018
484
Association between apolipoprotein E genotypes and panic disorder in Turkish population. 61
29888635 2018
485
Mental health service use, depression, panic disorder and life events among Swedish young adults in 2000 and 2010: a repeated cross-sectional population study in Stockholm County, Sweden. 61
28367775 2018
486
Posttraumatic Stress Symptoms and Emerging Adult Sexual Minority Men: Implications for Assessment and Treatment of Childhood Sexual Abuse. 61
30338584 2018
487
A pragmatic randomized controlled trial of group transdiagnostic cognitive-behaviour therapy for anxiety disorders in primary care: study protocol. 61
30285672 2018
488
Early effects of exposure-based cognitive behaviour therapy on the neural correlates of anxiety. 61
30341276 2018
489
Prospective associations between sleep problems and subtypes of anxiety symptoms among disaster-exposed adolescents. 61
29966810 2018
490
Does CBT for anxiety-related disorders alter suicidal ideation? Findings from a naturalistic sample. 61
30107264 2018
491
A functional genetic variation of SLC6A2 repressor hsa-miR-579-3p upregulates sympathetic noradrenergic processes of fear and anxiety. 61
30341278 2018
492
Learn to forget: Does post-exposure administration of d-cycloserine enhance fear extinction in agoraphobia? 61
30237105 2018
493
Prevalence of comorbid chronic pain and mental health conditions in Canadian Armed Forces active personnel: analysis of a cross-sectional survey. 61
30389752 2018
494
WHO World Mental Health Surveys International College Student Project: Prevalence and distribution of mental disorders. 61
30211576 2018
495
Meta-analysis of the influence of age on symptom change following cognitive-behavioural treatment for anxiety disorders. 61
30176552 2018
496
Transcranial sonography in psychiatry as a potential tool in diagnosis and research. 61
28971725 2018
497
Patterns and predictors of persistence of suicide ideation: Results from the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). 61
30335437 2018
498
The associations between non-suicidal self-injury and first onset suicidal thoughts and behaviors. 61
30014957 2018
499
Dismantling cognitive-behaviour therapy for panic disorder: a systematic review and component network meta-analysis. 61
29368665 2018
500
The role of acid-sensitive ion channels in panic disorder: a systematic review of animal studies and meta-analysis of human studies. 61
30194289 2018
501
The Revised-Panic Screening Score for emergency department patients with noncardiac chest pain. 61
30138020 2018
502
Efficacy of the Unified Protocol for transdiagnostic treatment of comorbid psychopathology accompanying emotional disorders compared to treatments targeting single disorders. 61
30103069 2018
503
Effect of terbutaline combined with budesonide in treatment of bronchial asthma and rehabilitation nursing. 61
30463820 2018
504
Severe role impairment associated with mental disorders: Results of the WHO World Mental Health Surveys International College Student Project. 61
29847006 2018
505
Early scars are forever: Childhood abuse in patients with adult-onset PTSD is associated with increased prevalence and severity of psychiatric comorbidity. 61
29879599 2018
506
Investigating effective treatment factors in brief cognitive behavioral therapy for panic disorder. 61
30235717 2018
507
Anxiety disorders and CRP in a population cohort study with 54,326 participants: The LifeLines study. 61
29376460 2018
508
Predictors of remission from panic disorder, agoraphobia and specific phobia in outpatients receiving exposure therapy: The importance of positive mental health. 61
29981937 2018
509
Twelve-Month Outcomes Following Successful Panic-Focused Psychodynamic Psychotherapy, Cognitive-Behavioral Therapy, or Applied Relaxation Training for Panic Disorder. 61
30256548 2018
510
Automatic Extraction of Mental Health Disorders From Domestic Violence Police Narratives: Text Mining Study. 61
30213778 2018
511
Executive function and other cognitive deficits are distal risk factors of generalized anxiety disorder 9 years later. 61
29224581 2018
512
Suicidal ideation in primary care patients suffering from panic disorder with or without agoraphobia. 61
30249220 2018
513
Evidence for cardiotoxicity associated with sertraline in rats. 61
30310659 2018
514
Personality functioning in anxiety disorders. 61
30223818 2018
515
Body Image Dissatisfaction and Anxiety Trajectories During Adolescence. 61
29087230 2018
516
Identification and Treatment of Peripartum Anxiety Disorders. 61
30092922 2018
517
Stress-induced pro- and anti-inflammatory cytokine concentrations in panic disorder patients. 61
29754003 2018
518
The Prescription of Benzodiazepines for Panic Disorder: Time for an Evidence-Based Educational Approach. 61
29912790 2018
519
Is 472G/A catechol-O-methyl-transferase gene polymorphism related to panic disorder?: Erratum. 61
29957743 2018
520
Effect of high-frequency repetitive transcranial magnetic stimulation (rTMS) in patients with comorbid panic disorder and major depression. 61
29737182 2018
521
Common Sleep, Psychiatric, and Somatic Problems According to Work Schedule: an Internet Survey in an Eastern European Country. 61
29557074 2018
522
Are there advances in pharmacotherapy for panic disorder? A systematic review of the past five years. 61
30063164 2018
523
Impaired discriminative fear conditioning during later training trials differentiates generalized anxiety disorder, but not panic disorder, from healthy control participants. 61
30005181 2018
524
The predictive specificity of psychological vulnerability markers for the course of affective disorders. 61
29758471 2018
525
Symptoms of swallowing anxiety in panic disorder patients and associated psychopathologic factors. 61
28229356 2018
526
Neuropsychiatric Lyme Borreliosis: An Overview with a Focus on a Specialty Psychiatrist's Clinical Practice. 61
30149626 2018
527
Dimensional and Categorical Correlates of Substance Use Disorders among Canadian Adolescents with Bipolar Disorder. 61
30038653 2018
528
Ethnic Groups Differ in How Poor Self-Rated Mental Health Reflects Psychiatric Disorders. 61
28913713 2018
529
Respiratory subtype of panic disorder: Can serum phosphate levels be a possible outcome to group cognitive-behavior therapy? 61
29680728 2018
530
Calibrating actigraphy to improve sleep efficiency estimates. 61
29063639 2018
531
Panic results in unique molecular and network changes in the amygdala that facilitate fear responses. 61
30108314 2018
532
Panic and epilepsy in adults: A systematic review. 61
29940374 2018
533
Temperament clusters associate with anxiety disorder comorbidity in depression. 61
29751240 2018
534
A Prospective Study of Psychiatric Symptoms Among Adolescents After the Wenchuan Earthquake. 61
30084507 2018
535
Can Religious Coping and Depressive Symptoms Predict Clinical Outcome and Quality of Life in Panic Disorder? A Brazilian Longitudinal Study. 61
29905662 2018
536
Comparing individually tailored to disorder-specific internet-based cognitive-behavioural therapy: benchmarking study. 61
30083380 2018
537
Interplay between COMT Val158Met, childhood adversities and sex in predicting panic pathology: Findings from a general population sample. 61
29574383 2018
538
Relative burst amplitude of muscle sympathetic nerve activity is an indicator of altered sympathetic outflow in chronic anxiety. 61
29537916 2018
539
Patients' characteristics and their influence on course of fear during agoraphobic symptom provocation: may SS(N)RI treatment compensate unfavorable individual preconditions? 61
29644923 2018
540
Examining predictors of help-seeking behaviours in patients with mood and anxiety symptoms. 61
29729499 2018
541
Anxiety sensitivity as a predictor of panic disorder symptoms: a prospective 3-year study. 61
29558829 2018
542
Unpredictable chronic prenatal stress and manifestation of generalized anxiety and panic in rat's offspring. 61
29596996 2018
543
Patterns of benzodiazepines use in primary care adults with anxiety disorders. 61
29998202 2018
544
Biases in Interpretation as a Vulnerability Factor for Children of Parents With an Anxiety Disorder. 61
29960691 2018
545
The unique and interactive effects of anxiety sensitivity and emotion dysregulation in relation to posttraumatic stress, depressive, and anxiety symptoms among trauma-exposed firefighters. 61
29694933 2018
546
Increased prevalence of anxiety disorders in third-generation migrants in comparison to natives and to first-generation migrants. 61
29597072 2018
547
Age Differences in Death and Suicidal Ideation in Anxious Primary Care Patients. 61
28960158 2018
548
Dynamic Gender Presentations: Understanding Transition and "De-Transition" Among Transgender Youth. 61
29960687 2018
549
Integration of EMDR and CBT Techniques in Treatment of Panic Disorder with Agoraphobia - A Case Report. 61
30095822 2018
550
The association of panic and hyperventilation with psychogenic non-epileptic seizures: A systematic review and meta-analysis. 61
29787922 2018
551
Anxiety disorders and figural fluency: A measure of executive function. 61
29522942 2018
552
Moving to Beat Anxiety: Epidemiology and Therapeutic Issues with Physical Activity for Anxiety. 61
30043270 2018
553
Correlates and management of comorbid anxiety disorders in schizophrenia. 61
31359983 2018
554
Alprazolam-induced dose-dependent anorgasmia: case analysis. 61
30083378 2018
555
Potential Impact of COMT-rs4680 G > A Gene Polymorphism in Coronary Artery Disease. 61
30011860 2018
556
The DSM-5 nonsuicidal self-injury disorder among incoming college students: Prevalence and associations with 12-month mental disorders and suicidal thoughts and behaviors. 61
29697881 2018
557
Prevalence of Tanning Addiction and Behavioral Health Conditions among Ethnically and Racially Diverse Adolescents. 61
29481903 2018
558
Is cognitive-behavioural therapy more effective than relaxation therapy in the treatment of anxiety disorders? A meta-analysis. 61
29037266 2018
559
Predictors of etiological beliefs about panic disorder and impact of beliefs on treatment outcomes. 61
29635142 2018
560
Changes in perceived centrality of anxious events following cognitive behavioral therapy for social anxiety disorder and panic disorder. 61
29425950 2018
561
Hypoventilation Therapy Alleviates Panic by Repeated Induction of Dyspnea. 61
29573981 2018
562
Differential electrophysiological correlates of panic disorder in non-pulsatile tinnitus. 61
29773153 2018
563
Dynamics of Defensive Response Mobilization to Approaching External Versus Interoceptive Threat. 61
29884283 2018
564
Auricular Chromotherapy in the Treatment of Psychologic Trauma, Phobias, and Panic Disorder. 61
29937969 2018
565
Amiloride modulation of carbon dioxide hypersensitivity and thermal nociceptive hypersensitivity induced by interference with early maternal environment. 61
29968500 2018
566
Clinical and functional outcomes of cannabis use among individuals with anxiety disorders: A 3-year population-based longitudinal study. 61
29486095 2018
567
Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. 61
29706139 2018
568
Running for extinction? Aerobic exercise as an augmentation of exposure therapy in panic disorder with agoraphobia. 61
29539585 2018
569
Association of Cannabis With Long-Term Clinical Symptoms in Anxiety and Mood Disorders: A Systematic Review of Prospective Studies. 61
29877641 2018
570
The relationship between impulsivity and panic disorder-agoraphobia: The role of affective temperament. 61
29649673 2018
571
Varieties of Self Disorder: A Bio-Pheno-Social Model of Schizophrenia. 61
29529266 2018
572
Flushing Disorders Associated with Gastrointestinal Symptoms: Part 1, Neuroendocrine Tumors, Mast Cell Disorders and Hyperbasophila. 61
29650525 2018
573
Anxiety and depression states of adolescents with polycystic ovary syndrome 61
29914248 2018
574
Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. 61
29451967 2018
575
Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis. 61
29659102 2018
576
Influence of comorbid alcohol use disorders on the clinical patterns of major depressive disorder: A general population-based study. 61
29626745 2018
577
Screening for panic-related anxiety in emergency department patients with cardiopulmonary complaints: A comparison of two self-report instruments. 61
29482044 2018
578
Hypoplastic Straight Sinus with Persistent Falcine Sinus in Adult with Sinus Pericranii. 61
29452321 2018
579
Environmental enrichment decreases avoidance responses in the elevated T-maze and delta FosB immunoreactivity in anxiety-related brain regions. 61
29448033 2018
580
Varenicline-Induced Panic Disorder in a Previously Healthy Patient. 61
29363353 2018
581
Specific amygdala response to masked fearful faces in post-traumatic stress relative to other anxiety disorders. 61
28950918 2018
582
Posttraumatic stress disorder as a growth industry: Comment on Asmundson and Asmundson (2018). 61
29859658 2018
583
Prevalence and treatment of panic disorder in bipolar disorder: systematic review and meta-analysis. 61
29636354 2018
584
Internet-based treatment for panic disorder: A three-arm randomized controlled trial comparing guided (via real-time video sessions) with unguided self-help treatment and a waitlist control. PAXPD study results. 61
29625834 2018
585
Military Personnel Who Seek Health and Mental Health Services Outside the Military. 61
29415229 2018
586
A Web-Based Transdiagnostic Intervention for Affective and Mood Disorders: Randomized Controlled Trial. 61
29798831 2018
587
Psychiatric symptoms in preclinical behavioural-variant frontotemporal dementia in MAPT mutation carriers. 61
29353234 2018
588
Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. 61
29492960 2018
589
Anticholinergic drug atropine diminishes newly formed fear memory in male rats. 61
29731446 2018
590
Pre-disaster PTSD as a moderator of the relationship between natural disaster and suicidal ideation over time. 61
29355729 2018
591
Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: An updated meta-analysis. 61
29422409 2018
592
Associations of Comorbid Anxiety With Medication Adherence and Psychiatric Symptomatology in a Population of Nonadherent Bipolar Disorder Subjects. 61
29351117 2018
593
Integrating Hypnosis with Other Therapies for Treating Specific Phobias: A Case Series. 61
29485374 2018
594
Both anxiety and joint laxity determine the olfactory features in panic disorder. 61
28923431 2018
595
Face Perception in Social Anxiety: Visuocortical Dynamics Reveal Propensities for Hypervigilance or Avoidance. 61
29157845 2018
596
[The Jena Anxiety Monitoring List (JAMoL) - a tool for the evidence-based treatment of panic disorder with or without agoraphobia in primary care]. 61
29544715 2018
597
Psychiatric Sequelae of Former "Comfort Women," Survivors of the Japanese Military Sexual Slavery during World War II. 61
29669407 2018
598
Antidepressants versus placebo for panic disorder in adults. 61
29620793 2018
599
A systematic review of variables associated with sleep paralysis. 61
28735779 2018
600
Bipolar disorder and tobacco smoking: Categorical and dimensional clinical correlates in subjects from the Brazilian bipolar research network. 61
29367058 2018
601
Child Maltreatment and Clinical Outcome in Individuals at Ultra-High Risk for Psychosis in the EU-GEI High Risk Study. 61
28666366 2018
602
[Usual Care for Panic Disorder with/without Agoraphobia in Primary Care]. 61
28499315 2018
603
Endometriosis increased the risk of bladder pain syndrome/interstitial cystitis: A population-based study. 61
29318645 2018
604
Relationship of bipolar disorder with psychiatric comorbidity in the postpartum period-a scoping review. 61
29067549 2018
605
Predictors of benzodiazepine use in a transdiagnostic sample of panic disorder, social anxiety disorder, and obsessive-compulsive disorder patients. 61
29475102 2018
606
DiGeorge syndrome : Relevance of psychiatric symptoms in undiagnosed adult patients. 61
29671046 2018
607
Risks and benefits of medications for panic disorder: a comparison of SSRIs and benzodiazepines. 61
29357714 2018
608
Haptoglobin Phenotype Among Arab Patients With Mental Disorders. 61
29416577 2018
609
Cytokine alterations in panic disorder: A systematic review. 61
29241050 2018
610
Psychometric Properties of the Spanish Version of the Panic Disorder Severity Scale. 61
29573755 2018
611
The effect of panic disorder versus anxiety sensitivity on event-related potentials during anticipation of threat. 61
29291580 2018
612
The regional homogeneity of cingulate-precuneus regions: The putative biomarker for depression and anxiety. 61
29316519 2018
613
TMEM132: an ancient architecture of cohesin and immunoglobulin domains define a new family of neural adhesion molecules. 61
29088312 2018
614
Sex differences in stress responses: a critical role for corticotropin-releasing factor. 61
29858858 2018
615
Lesional Temporal Lobe Epilepsy: Beware the Deceitful "Panic Attack". 61
29288854 2018
616
Influence of military component and deployment-related experiences on mental disorders among Canadian military personnel who deployed to Afghanistan: a cross-sectional survey. 61
29530906 2018
617
What is the effect on comorbid personality disorder of brief panic-focused psychotherapy in patients with panic disorder? 61
29212135 2018
618
Physiological and pathophysiological firing properties of single postganglionic sympathetic neurons in humans. 61
29142091 2018
619
[Anxiety disorders: which psychotherapy for whom?] 61
29383412 2018
620
Association between COMT Val158Met and psychiatric disorders: A comprehensive meta-analysis. 61
28608575 2018
621
Nineteen and Up study (19Up): understanding pathways to mental health disorders in young Australian twins. 61
29550775 2018
622
Social Support and Symptom Severity Among Patients With Obsessive-Compulsive Disorder or Panic Disorder With Agoraphobia: A Systematic Review. 61
29899808 2018
623
Suicidality in Subjects With Anxiety or Obsessive-Compulsive and Related Disorders: Recent Advances. 61
29594718 2018
624
Whole-exome sequencing and gene-based rare variant association tests suggest that PLA2G4E might be a risk gene for panic disorder. 61
29391400 2018
625
Cue and context conditioning to respiratory threat: Effects of suffocation fear and implications for the etiology of panic disorder. 61
29330006 2018
626
Panic-like escape response elicited in mice by exposure to CO2, but not hypoxia. 61
29111406 2018
627
Stress hormone response to the DEX-CRH test and its relation to psychotherapy outcome in panic disorder patients with and without agoraphobia. 61
29391399 2018
628
Transdiagnostic Symptom Clusters and Associations With Brain, Behavior, and Daily Function in Mood, Anxiety, and Trauma Disorders. 61
29197929 2018
629
[Ability of French General Practitioners to detect common mental disorders identified using the Patient Health Questionnaire: Has this changed with the introduction of gatekeeping and registration with a chosen doctor?] 61
27751560 2018
630
Prevalence and comorbidity of sleep conditions in Australian adults: 2016 Sleep Health Foundation national survey. 61
29332673 2018
631
Association between sleep disorder and panic disorder in South Korea: Nationwide nested case-control study of data from 2004 to 2013. 61
29223044 2018
632
Prevalence of anxiety disorders in epilepsy. 61
29223931 2018
633